Zealand Pharma sends obesity candidate to clinic

Zealand Pharma has started a phase I study of the drug candidate ZP8396, which the company hopes will become an effective treatment for obesity. The trial is expected to be finished in September 2022.
Emmanuel Dulac - CEO at Zealand Pharma | Photo: Stine Bidstrup ERH
Emmanuel Dulac - CEO at Zealand Pharma | Photo: Stine Bidstrup ERH
by albert rønning-andersen, translated by catherine brett

Danish pharmaceutical company Zealand Pharma wants a slice of the lucrative market for obesity treatments.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading